← All trials
NCT05766904
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2023
- Primary completion
- Mar 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Mar 13, 2023
- Last posted
- May 16, 2023
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese University of Hong KongLead sponsor
- Chinese University of Hong KongReponsible party - principal investigator
- Chinese University of Hong KongOfficial
- Chinese University of Hong KongSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.